UCB is a global biopharmaceutical company, with a focus on neurology and immunology. Our business is strong. Total revenue grew to €4.2 billion in 2016. We are more than 7,700 people in all four corners of the globe, inspired by patients and driven by science. Looking ahead, we have a solid platform for continuous growth with our core products Cimzia®, Vimpat®, Neupro®, Keppra® and Briviact®, and we are preparing the launch of a potential medicine to help patients with osteoporosis. At the same time, we are very excited about the progress in our early research pipeline.
The UK premises of UCB are located in Slough, Berkshire. The site at Slough houses the immunology research hub and the head office for the British and Irish Isles (BII) commercial organisation. Antibody research and early antibody development functions are also located in Slough alongside some manufacturing and corporate functions. UCB employs approximately 740 people in the UK and Ireland, of which 400 are engaged in Research & Development.